Natural History After Likely Cure Versus Recurrence After Prostate Radiotherapy (RAPTOR).

Authors

Soumyajit Roy, Tahmineh Romero, Mack Roach, Jeff M Michalski, David J Joseph, David Dearnaley, Alison C Tree, Emma Hall, Matthew R Sydes, Luca Incrocci, Wilma Heemsbergen, Floris de Pos, Michel Bolla, Philippe Maingon, Theo de Reijke, Abdenour Nabid, John G Armstrong, Scott C Morgan, Xavier Maldonado, Wee L Ong, Jarad Martin, Eric M Horwitz, Jessica K Wong, Michael Steinberg, Luca Valle, Kekoa Taparra, Angela Y Jia, Nicholas G Zaorsky, Stefano Arcangeli, Giuseppe Sanguineti, Almudena Zapatero, Howard Sandler, Paul L Nguyen, Yilun Sun, Daniel E Spratt, Amar U Kishan

Published in

European urology oncology. Oct 01, 2026. Epub Oct 01, 2026.

Abstract

Whether freedom from biochemical recurrence (BCR) at 5 yr after definitive radiotherapy (RT) for localized prostate cancer (PCa) represents a durable cure remains uncertain.
To evaluate the association between the timing of BCR after RT and the long-term risks of distant metastasis (DM) and PCa-specific mortality (PCSM), overall and according to treatment intensity, including outcomes by BCR timing (≤5 yr, >5 yr, or no BCR).
Post hoc individual patient data analysis of 3120 men with intermediate- (89%) or high-risk (11%) PCa enrolled in 11 randomized trials within the Meta-Analysis of Randomized Trials in Cancer of the Prostate consortium and treated with contemporary high-dose RT (HDRT) ± androgen deprivation therapy (ADT).
Cumulative incidences of DM at 8 yr and PCSM at 10 yr after RT were estimated using competing-risk methods. Adjusted cumulative incidences were estimated using average marginal effects, accounting for clinicopathologic factors, treatment intensity, and progressively longer durations remaining free of BCR after RT. A priori, cumulative incidences ≤10% were considered indicative of a favorable long-term prognosis.
Among men without BCR at 5 yr, subsequent risks of DM and PCSM were low overall. In patients with intermediate-risk PCa treated with HDRT alone, the adjusted cumulative incidences of 8-yr DM and 10-yr PCSM were 6.6% and 2.5%, respectively, indicating a favorable long-term prognosis based on the prespecified threshold. In contrast, patients with intermediate-risk PCa treated with HDRT plus short-term ADT and patients with high-risk PCa treated with HDRT plus long-term ADT had higher residual metastatic risk (8-yr adjusted cumulative DM incidence of 11% and 16%, respectively) exceeding the predefined favorable prognosis threshold despite remaining BCR-free for 5 yr. Early BCR (≤5 yr) was associated with substantially higher risks of DM and PCSM across all treatment groups. Limitations include the retrospective nature of the analyses, heterogeneity in BCR definitions across trials, absence of comorbidity data and contemporary risk subclassification, and the pre-prostate-specific membrane antigen imaging era of the constituent trials.
A 5-yr BCR-free benchmark was associated with a favorable long-term prognosis for intermediate-risk PCa treated with RT alone, but it appears insufficient for patients requiring ADT intensification. External validation in contemporary cohorts with standardized BCR definitions and modern imaging is warranted.

PMID:
42823260
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.